Treatment of disease or injury of the nervous system with FTY720
Methods for modulating neurogenesis in vitro and in vivo have been disclosed. The methods comprise contacting neural stem cells with an effective amount of a FTY720 compound. The neurogenesis may involve the modulation of proliferation, differentiation, migration or survival of a non-embryonic neural stem cells or progenitor cells. Also disclosed are methods for the prevention or treatment of neurological disorders comprising administering to a subject a therapeutically effective amount of a FTY720 compound. The disorders that can be treated include various nervous system disorders.
1 . A method for modulating neurogenesis in a subject comprising contacting cells in neural tissue in the subject with a composition comprising FTY720 or a derivative thereof in an amount sufficient to modulate neurogenesis.
2 . The method of claim 1 , wherein modulating neurogenesis is modulating proliferation, differentiation, migration, or survival of neural stem cells or neural progenitor cells.
3 . The method of claim 2 , wherein the neural stem cells or neural progenitor cells are non-embryonic cells.
4 . A method for increasing proliferation of neural stem cells comprising contacting the cells with a composition comprising FTY720 or a derivative thereof in an amount sufficient to increase the proliferation of the cells.
5 . The method of claim 4 , wherein the cells are non-embryonic cells.
6 . The method of claim 4 , wherein the derivative is FTY720P.
7 . The method of claim 4 , wherein the FTY720 or derivative is added to the cells to obtain a concentration of 0.001 nM to 0.05 nM.
8 . The method of claim 4 , wherein the FTY720 or derivative is added to the cells to obtain a concentration of 0.02 nM to 0.04 nM.
9 . The method of claim 4 , wherein the cells are mammalian cells.
10 . The method of claim 9 , wherein the cells are human cells.
11 . The method of claim 10 , wherein the cells are adult cells.
12 . The method of claim 4 , wherein the cells are also contacted with one or more growth factors.
13 . A method for alleviating a symptom of a nervous system disorder in a subject comprising administering a composition comprising FTY720 or a derivative thereof to the subject in an amount sufficient to alleviate the symptom.
14 . The method of claim 13 , wherein the derivative is FTY720P.
15 . The method of claim 13 , wherein the nervous system disorder is selected from the group consisting of neurodegenerative disorders, neural stem cell disorders, neural progenitor disorders, ischemic disorders, neurological traumas and injuries, affective disorders, neuropsychiatric disorders, degenerative diseases of the retina, retinal injury and trauma, and learning and memory disorders.
16 . The method of claim 13 , wherein the nervous system disorder is selected from the group consisting of Parkinson's disease, Parkinsonian disorders, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal ischemia, ischemic stroke, spinal cord injury, cancer-related brain injury, and cancer-related spinal cord injury, Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease, stroke, cerebral infarction, multi-infarct dementia, and geriatric dementia.
17 . The method of claim 13 , wherein the FTY720 or derivative is administered at a concentration of 1 ng/kg/day to 1 mg/kg/day.
18 . The method of claim 13 , wherein the FTY720 or derivative is administered at a concentration of 1 μg/kg/day to 0.1 mg/kg/day.
19 . The method of claim 13 , wherein the FTY720 or derivative is administered at a concentration of 5 μg/kg to approximately 0.07 mg/kg.
20 . The method of claim 13 , wherein the FTY720 or derivative is administered at an amount of 0.3 mg to 10 mg.
21 . The method of claim 13 , wherein the subject is a mammal.
22 . The method of claim 21 , wherein the subject is a human.
23 . The method of claim 22 , wherein the subject is an adult.
24 . The method of claim 13 , wherein the subject is also administered one or more growth factors.
25 . The method of claim 13 , wherein the subject is also administered one or more agents selected from the group consisting of anti-depressants, anti-anxiety treatments, anti-psychotic treatments, epilepsy treatments, Alzheimer's treatments, Parkinson's treatments, MAO inhibitors, serotonin-uptake blockers, noradrenaline uptake blockers, dopamine uptake blockers, dopamine agonists, L-DOPA, tranquilizers, sedatives, and lithium.
26 . The method of claim 13 , wherein the composition is administered systemically.
27 . The method of claim 13 , wherein the composition is administered by a route selected from the group consisting of oral, subcutaneous, intraperitoneal, intramuscular, intraventricular, intraparenchymal, intrathecal, intracranial, buccal, mucosal, nasal, and rectal routes.
28 . The method of claim 13 , wherein the composition is formulated as a nasal spray or nasal suppository.
29 . The method of claim 28 , wherein the composition is administered by a dry powder inhaler or aqueous-based inhaler.
30 . The method of claim 13 , wherein the FTY720 or a derivative thereof is administered to a central nervous system of the subject.
31 . A method for increasing the proliferation of non-embryonic neural stem cells in vitro comprising contacting the cells with a composition comprising FTY720 or a derivative thereof in an amount sufficient to increase the proliferation of the cells.
32 . The method of claim 31 , wherein the derivative is FTY720P.
33 . The method of claim 31 , wherein the FTY720 or derivative is added to the cells at a concentration of 0.001 nM to 0.05 nM.
34 . The method of claim 31 , wherein the FTY720 or derivative is added to the cells at a concentration of 0.02 nM to 0.04 nM.
35 . The method of claim 31 , wherein the cells are mammalian cells.
36 . The method of claim 35 , wherein the cells are human cells.
37 . The method of claim 36 , wherein the cells are adult cells.
38 . The method of claim 31 , wherein the cells are also contacted with one or more growth factors.